1. Home
  2. IMCC vs PFSA Comparison

IMCC vs PFSA Comparison

Compare IMCC & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IM Cannabis Corp.

IMCC

IM Cannabis Corp.

HOLD

Current Price

$0.14

Market Cap

1.4M

Sector

Health Care

ML Signal

HOLD

PFSA

Profusa Inc.

HOLD

Current Price

$1.80

Market Cap

1.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMCC
PFSA
Founded
1980
2009
Country
Israel
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4M
1.7M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
IMCC
PFSA
Price
$0.14
$1.80
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.9M
2.1M
Earning Date
05-08-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$63.88
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.05
52 Week High
$3.13
$4.22

Technical Indicators

Market Signals
Indicator
IMCC
PFSA
Relative Strength Index (RSI) 37.75 62.81
Support Level $0.12 $0.21
Resistance Level $0.17 $2.25
Average True Range (ATR) 0.01 0.24
MACD 0.00 0.08
Stochastic Oscillator 28.82 57.99

Price Performance

Historical Comparison
IMCC
PFSA

About IMCC IM Cannabis Corp.

IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority revenue is generated from Germany, and also has its presence in Israel.

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.

Share on Social Networks: